4. konkurs w ramach ERA-CVD Cardiovascular Diseases

Under the umbrella of ERA-CVD, the fourth joint transnational call JTC2019 is now launched to promote co-operation and interchange between Early Career Scientists1 and thus enable international collaboration and new consortia establishment in all cardiovascular areas.

The ERA-CVD funding organizations particularly wish to promote multi-disciplinary work and translational research proposals. The individual components of joint applications should be complementary and contain novel, ambitious ideas to answer key questions or lead to a step-wise change in understanding of cardiovascular diseases. There should be a clear added value in funding the collaboration over individual projects by sharing of resources (models, databases, diagnosis etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies.

Hence, JTC2019 aims at enabling Early Career Scientists2 in different countries to build effective collaborations and interchange on common multidisciplinary research projects, hence establish new consortia in cardiovascular disease. The opportunity to independently develop and perform highly innovative research projects enables capacity building and empowering of Early Career Scientists. The consortia should be based on complementarities and sharing of expertise in a field of CVD, with a clear translational research approach.

Eligible research topics in this call can comprise hypertensive, ischaemic, pulmonary heart dis-eases and diseases of pulmonary circulation, other forms of heart disease, diseases of arteries, arterioles and capillaries and congenital malformations of cardiac chambers and connections, rheumatic diseases and cardiac septa (analogues to ICD-10).

Applicants should consider the following cross-sectional aspects:

• Interdisciplinary approach, e.g. integrating biomedicine, physics, chemistry, mathematics, informatics, systems biology and clinical medicine for the development of the applications;

• Research on sex/gender differences in order to give further mechanistic insights into the development of the disease, its progression and to identify difference in treatment responses;

• Translational research: from pre-clinical up to phase 1;

No funding can be provided for co-funding or supplementary funding for already existing studies.

The following types of research projects are excluded from the call:

• Interventional clinical trials (phase 2, 3 and 4);

• Building up of new cohorts, registries and/or biomaterial banks;

• Cerebrovascular diseases;

• Research that primarily leads to cardiovascular risk management. Risk management is understood as long term health improvement and/or coronary artery disease (CAD) pre-vention;

• Conducting screenings